Managing partner; HTA expert
payer GmbH, Germany
Dr. Antje Behring is a pharmacist with extensive experience in evidence-based medicine and the health technology assessment (HTA) of medicinal products.
She studied pharmacy and obtained her PhD in the field of cardiovascular diseases. She began her professional career as a consulting pharmacist at a regional health insurance fund (payer), advising on the economic aspects of pharmaceutical care and health policy issues.
From 2011 to 2024, Dr. Behring worked in the Pharmaceuticals Department of the Federal Joint Committee (G-BA). Following the introduction of the German Pharmaceutical Market Restructuring Act (AMNOG), she contributed to the implementation of early benefit assessments of new medicines in Germany. She was also actively involved in integrating Germany into the European Health Technology Assessment (EU HTA) framework, promoting close coordination between national and European evaluation and consultation processes.
Before studying pharmacy, Dr. Behring gained practical experience as a physiotherapist in both outpatient and inpatient care settings.
Since 2024, she has been working for the pharmaceutical industry association Pharma Deutschland, where she focuses on key topics such as HTA in Germany and Europe, pricing and reimbursement, as well as innovation and research in the pharmaceutical sector.
Navigating the New Frontier: The Impact of Joint Clinical Assessments on Regulatory Affairs
Wednesday, October 8, 2025
1:00 PM - 2:00 PM EST